Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01736579 · ClinicalTrials.gov registry record · Phase 3
Long-Term Study of IGIV, 10% in Alzheimer´s Disease
A Phase 3 study, sponsored by Baxalta now part of Shire.
- Terminated
- Registry status
- Phase 3
- Development phase
- 6
- Enrollment target
NCT01736579: Clinical Trial Phase 3 study, sponsored by Baxalta now part of Shire.
NCT01736579 is a Phase 3 study that was terminated before completion, run by Baxalta now part of Shire. The registered enrollment target is 6 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01736579, a Phase 3 study, was terminated before completion, sponsored by Baxalta now part of Shire.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this long-term study is to provide additional evidence of safety and efficacy of IGIV, 10% treatment in participants with Alzheimer´s Disease who have completed the Phase 3 Baxter precursor study 160701. All participants will receive IGIV, 10% at either 0.2 g/kg or 0.4 g/kg body weight depending on their treatment assignment in Baxter study 160701. Participants and investigators will be blinded to dose unless otherwise notified by the sponsor.
Interventions
- DRUG Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2012-11-29 |
| Est. Completion | 2013-06-04 |
| Phase | Phase 3 |
Why NCT01736579 stopped before completion
NCT01736579 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Immune Globulin Intravenous (Human), 10% (IGIV, 10%) is the first listed.
NCT01736579 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01736579 about?
NCT01736579 is a clinical study titled "Long-Term Study of IGIV, 10% in Alzheimer´s Disease". The purpose of this long-term study is to provide additional evidence of safety and efficacy of IGIV, 10% treatment in participants with Alzheimer´s Disease who have completed the Phase 3 Baxter precursor study 160701. All participants will receive IGIV, 10% at either 0.2 g/kg or 0.4 g/kg body weigh...
What is the current status of trial NCT01736579?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 6 participants. The study started on 2012-11-29. Estimated completion is 2013-06-04.
What interventions are being tested in trial NCT01736579?
The interventions under investigation include: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) (DRUG).
Who is sponsoring clinical trial NCT01736579?
This trial is sponsored by Baxalta now part of Shire, which has 74 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01736579's enrollment target sits among peer trials
6 1995th of 2000 higher than 4 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI